Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Velaglucerase alfa - Takeda

Next Previous
Drug Profile

Velaglucerase alfa - Takeda

Alternative Names: GA-GCB; GCB; Gene-activated glucocerebrosidase; Glucocerebrosidase - Takeda; Glucosylceramidase - Takeda; Vpriv

Latest Information Update: 04 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Shire; Takeda
  • Class Glucosidases; Recombinant proteins
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease type I
  • No development reported Gaucher's disease type III

Most Recent Events

  • 05 Aug 2024 Takeda completes a phase III trial in Gaucher's disease type I (In children, In adolescents, In adults) in China (IV, Infusion) (NCT05529992)
  • 03 Jan 2023 Phase-III clinical trials in Gaucher's disease type I (In children, In adults, In adolescents, In the elderly) in China (IV) (NCT05529992; EudraCT2022-002323-35)
  • 07 Sep 2022 Takeda plans a phase III trial for Gaucher's disease type I (In children, In adolescents, In adults) in China (IV, Infusion) (NCT05529992)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top